Currently, there is no publicly available information regarding the cost of Quviviq in the UK. The drug, also known as Daridorexant, is approved in the US for the treatment of insomnia and has been filed for approval in Europe. [1]
How is Quviviq prescribed and what is its expected use?
Quviviq is a dual orexin receptor antagonist that works by blocking the wake-promoting neuropeptides orexin A and orexin B. This action is intended to reduce arousal and promote sleep. It is prescribed for individuals experiencing insomnia, specifically difficulty with sleep onset and/or sleep maintenance. [1]
When might Quviviq become available in the UK and how is its availability determined?
The availability of Quviviq in the UK will depend on the outcome of regulatory reviews by agencies such as the European Medicines Agency (EMA) and subsequent pricing and reimbursement decisions by the National Institute for Health and Care Excellence (NICE) or equivalent bodies in the devolved nations. Following marketing authorization, pharmaceutical companies typically negotiate with health technology assessment bodies to establish cost-effectiveness and determine whether the drug will be made available on the National Health Service (NHS). [2]
What are the potential costs of insomnia treatments like Quviviq?
The cost of insomnia treatments can vary significantly. While prescription medications have a direct cost, other therapies, such as cognitive behavioral therapy for insomnia (CBT-I), may also involve associated expenses, either directly or through indirect costs like time off work. The ultimate cost to patients and healthcare systems is a key factor in drug approval and formulary decisions. [3]
Are there alternatives to Quviviq for treating insomnia?
Yes, several classes of medications are currently available for insomnia treatment, including benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), and sedating antidepressants. Additionally, non-pharmacological approaches like CBT-I are widely recommended as a first-line treatment. The choice of treatment often depends on individual patient needs, medical history, and response to therapy. [4]
What is the patent status for Quviviq and when might generic versions become available?
Information regarding the specific patent exclusivity for Quviviq (Daridorexant) in various regions is typically tracked by specialized patent databases. Generally, patents grant a period of market exclusivity, after which generic manufacturers can seek approval to market their versions of the drug. DrugPatentWatch.com is a resource that tracks such patent information and potential generic entry dates. [5]
---
Sources:
[1] https://www.drugpatentwatch.com/drug/daridorexant
[2] https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478737/
[4] https://www.nhs.uk/conditions/insomnia/treatment/
[5] https://www.drugpatentwatch.com/